Advancing the Future of Biomarker-Driven Immunotherapy

Can spatial biomarkers revolutionize patient stratification for immune checkpoint inhibitors?

Join us for an exclusive webinar exploring groundbreaking findings from the DUTRENEO trial, which evaluated the role of predictive biomarkers in guiding neoadjuvant therapy for muscle-invasive bladder cancer (MIBC). While traditional biomarker strategies have struggled to prospectively enrich for responders, cutting-edge multi-omics and spatial transcriptomics are shedding new light on the biological determinants of therapy success.

We’ll explore:

The Role of Spatial Biomarkers – Discover how tumor-immune architecture and cellular neighborhoods influence response to ICI therapy.
Multi-Omics Breakthroughs – Learn how whole-exome sequencing, RNA-seq, and the largest spatial transcriptomics dataset in bladder cancer research are transforming biomarker discovery.
Challenges in Predictive Biomarkers – Understand why retrospective biomarkers often fail in prospective trials and how spatially resolved, multi-modal approaches can improve patient stratification.
Implications for Future Clinical Trials – Explore how integrating spatial and phenotypic heterogeneity into biomarker-driven trial design can refine therapeutic selection.

Don't miss this opportunity to gain deep insights from leading experts in oncology and biomarker research.